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Abstract
Background: The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has
served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive
cancers display de novo resistance to tamoxifen, and acquired resistance evolves in 40 % of patients who initially
respond. Mechanisms underlying resistance development remain poorly understood and new therapeutic
opportunities are urgently needed. Here, we report the generation and characterization of seven tamoxifen-resistant
breast cancer cell lines from four parental strains.
Methods: Using high throughput drug sensitivity and resistance testing (DSRT) with 279 approved and
investigational oncology drugs, exome-sequencing and network analysis, we for the first time, systematically
determine the drug response profiles specific to tamoxifen resistance.
Results: We discovered emerging vulnerabilities towards specific drugs, such as ERK1/2-, proteasome- and
BCL-family inhibitors as the cells became tamoxifen-resistant. Co-resistance to other drugs such as the survivin
inhibitor YM155 and the chemotherapeutic agent paclitaxel also occurred.
Conclusion: This study indicates that multiple molecular mechanisms dictate endocrine resistance, resulting in
unexpected vulnerabilities to initially ineffective drugs, as well as in emerging co-resistances. Thus, combatting
drug-resistant tumors will require patient-tailored strategies in order to identify new drug vulnerabilities, and to
understand the associated co-resistance patterns.
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Background
Breast cancer is the most common cancer in women
worldwide. Two-thirds of breast tumors express ER that
drives proliferation of mammary epithelial cells and
thereby contributes to the etiology and progression of
the disease. Consequently, antagonists that directly block
ER function or drugs that lower the amounts of the nat-
ural ligand of ER, estradiol, have been utilized in breast
cancer treatment for decades [1]. For over 40 years,
tamoxifen, a selective ER antagonist, has been the back-
bone in treating ER-positive breast cancers. Despite of
being effective in decreasing mortality, de novo or ac-
quired resistance frequently occurs [2]. Some of the
mechanisms leading to resistance have been revealed, in-
cluding mutations in the gene encoding ER [3–5], al-
tered expression patterns of ER or its cofactors [6, 7],
and crosstalk between ER and growth factor receptor
cascades such as the EGFR/ERK1/2-pathway [8]. Conse-
quently, inhibition of ERK1/2 has been reported to re-
store antiestrogen sensitivity. For example, a study with
the MEK inhibitor PD098059, a compound that reduces
the phosphorylation and activation of ERK1/2, was
shown to inhibit the growth of tamoxifen-resistant cell
lines and to restore their sensitivity to therapy [9, 10].
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However, ERK1/2 inhibition has proven efficacy primar-
ily against cells with resistance-provoked overexpression
or activation of HER2 [9]. On the other hand, recent
findings suggest that proteasome inhibition might offer a
new avenue for overcoming endocrine resistance [11, 12].
Bortezomib, a proteasome inhibitor, has been investigated
as a combination therapy in conjunction with endocrine
treatment in a phase II study [13].
Whilst shRNA- or cDNA-based functional screens
[14, 15] and candidate gene [16–19], or drug [9, 20–23]
approaches have been used to study the development
and reversal of endocrine resistance, the exact molecu-
lar mechanisms remain unknown, and large-scale stud-
ies on cells treated long-term with tamoxifen are
lacking. Moreover, efforts to find new treatment regimes
for overcoming drug resistance have been largely based
on a few selected drug candidates, and have only proven
to be effective in a fraction of the cases [1]. Develop-
ment of primary drug resistance can make the cancer
cells susceptible for novel vulnerabilities, hence leading
to additional therapeutic opportunities. However, sec-
ondary resistances towards other drugs may also arise.
Resistance to chemotherapeutics has been linked with
estrogen receptor positive breast cancer [24], but system-
atic studies on tamoxifen resistance associated co-
resistances have not been conducted. Therefore, systematic,
large-scale studies to characterize the drug sensitivity pro-
files of tamoxifen-resistant breast cancer are warranted to
reveal new drug vulnerabilities as well as co-resistance pat-
terns in drug-resistant cells.
Here, we report the development and characterization of
a panel of seven long-term tamoxifen-treated breast cancer
cell lines from four parental strains. Using these resistant
cell line models and their isogenic parental counterparts,
we, for the first time, performed systematic high through-
put drug sensitivity and resistance testing with 279 ap-
proved and investigational oncology drugs to reveal
potential new drug vulnerabilities and to identify co-
resistance patterns acquired with tamoxifen resistance. We
further conducted exome-sequencing on each of the iso-
genic parental-resistant cell line pair to identify point mu-
tations and copy number variations that may contribute to
drug resistance. Through integrated network analyses, we
uncovered cell- and clone-specific molecular and functional
patterns of endocrine resistance, highlighting the underlying
molecular diversity, and pointing to several distinct thera-
peutic opportunities to circumvent it. However, no system-
atic drug screens with hundreds of oncology compounds
on acquired tamoxifen resistance have been conducted.
Methods
Cell culture
Human breast cancer cell lines MCF-7 (HTB-22,
ATCC), T-47D (HTB-133, ATCC), ZR-75-1 (CRL-1500,
ATCC) and BT-474 (HTB-20, ATCC) were obtained
from the American Type Culture Collection. The cells
were grown in DMEM with L-Glutamine (MCF-7 and
BT-474, PAN Biotech, Aidenbach, Germany) or RPMI-
1640 with L-Glutamine (ZR-75-1 and T-47D, PAN
Biotech) supplemented with 10 % FCS (Gibco, Life
Technologies, Carlsbad, CA) and 1 % penicillin/strepto-
mycin (Gibco). Culture media for T-47D, MCF-7 and
BT-474 additionally contained 0,1 % bovine insulin
(Sigma. St. Louis, MO). The tamoxifen-resistant cell
lines (MCF-7 Tam1, T-47D Tam1 & Tam2, ZR-75-1
Tam1 & Tam2, BT-474 Tam1 & Tam2) were derived
from the parental cell lines by continuous exposure to 4-
OH-tamoxifen (Sigma, 1 μM in ethanol) for 8–12
months. Culture media was replaced every 2–3 days. All
cells were incubated at 37 °C with 5 % CO2 and passaged
when ca 80 % confluent. The approximate doubling
times of the cells were as follows: parental MCF-7, T-
47D, ZR-75-1 and BT-474: 1–3 days. Resistant MCF-7
Tam1, T-47D Tam1 and Tam2: 1–2 weeks, ZR-75-1
Tam1 and Tam2: > 1 week, BT-474 Tam1 and Tam2:
2 weeks. The cells were free of mycoplasma and verified
for their authenticity (Technology Centre, Institute for
Molecular Medicine Finland, Helsinki, Finland).
Characterization of tamoxifen-resistant cell lines
For viability measurements cells were seeded in 384-well
culture plates with increasing tamoxifen concentrations
(0–1,8 μM). After 120 h cell viability was evaluated by
CellTiter-Glo Cell Viability Assay (Promega, Fitchburg,
WI) with the PHERAstar plate reader (Agilent Tech-
nologies Santa Clara, CA). To measure the active DNA
synthesis cell proliferation assays with Click-iT® EdU
Alexa Fluor® 488 Flow Cytometry Assay Kit were per-
formed according to manufacturer’s protocol (Life Tech-
nologies) with following minor modifications: Cells were
plated on 10 cm plates and cultured with and without
1 μM tamoxifen until approximately 50 % confluent.
Parental cells and their tamoxifen-resistant derivatives
were then pulsed with 10 μM of EdU Alexa Fluor® 488
for 4 h (T-47D and MCF-7) or for 28 h (BT-474 and
ZR-75-1). Cells were permeabilized with saponin-based
permeabilization and wash reagent (MCF-7, T-47D, BT-
474) or with 0,1 % TritonX-100-PBS (ZR-75-1) for
10 min. Additionally, DNA content staining was per-
formed using FxCycle™ Far Red and the cell suspension
treated with RibonucleaseA. Flow cytometry was carried
out and results analyzed using Accuri C6 flow cytometer
and associated software (BD Biosciences, Franklin Lakes,
NJ). To measure estrogen-responsivity of the parental
cells and their tamoxifen-resistant derivatives, the cells
were grown on 6-well plates in hormone-deprived cul-
ture medium for 72 h (phenol red-free DMEM or RPMI,
PAN Biotech), supplemented with 2,5 % dextran–
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charcoal-treated (Sigma-Aldrich) FCS and other addi-
tives (see above). 17β-estradiol (Sigma, 10−8 M in etha-
nol) was then added back to the cells for 4, 8 or 24 h
and RNA isolated with Total RNA Purification kit
(Norgen, Thorold, ON). 4 μg of total RNA were reverse
transcribed with the High-Capacity cDNA Reverse tran-
scription kit (Applied Biosystems, Thermo Scientific,
Waltham, MA) as instructed. Quantitative-PCR was
then performed on the LightCycler 480 system (Roche,
Penzberg, Germany) using the DyNAmo colour flash
SYBRGreen PCR kit (Thermo Scientific) with equal
amounts of cDNA. The optimal internal reference gene
was determined out of a pool of 16 different housekeep-
ing genes for each parental-resistant cell line pair (18S
for MCF-7 s, PPIA for T-47Ds and B2M for ZR-75-1 s
and BT-474 s). Primer sequences can be found in Add-
itional file 1. All experiments were done in triplicates.
For Western Blotting cells were grown on 10 cm dishes,
and lyzed in Laemmli buffer. Immunoblotting was done
as previously described [25]. The used antibodies were
as follows: ERα (Abcam, Cambridge, UK, ab16660), β-
actin (Sigma-Aldrich, A1978), EGFR (Cell Signaling
Technologies, CST4267), phospho-EGFR (CST3777),
ERK1/2 (CST9107), phospho-ERK1/2 (CST4370). To
test the effects the ERK inhibitor VX-11E and the MEK
inhibitor selumintinib the cells were cultured either in
their default culture media with no additional drug, or
with increasing concentrations of VX-11E (50nM,
100nM and 250nM), or with 100nM VX-11E in combin-
ation with 1 μM selumetinib. The cells were then har-
vested and Western blotting with the above-mentioned
antibodies performed.
Genomic profiling by exome-sequencing
Genomic DNA was isolated from the parental and
tamoxifen-resistant cells using the DNeasy Blood & Tis-
sue kit (Qiagen, Venlo, Netherlands and Hilden,
Germany). Exome-capture was done on 3 μg DNA with
the NimbleGen SeqCap EZ Human Exome v2.0 kit
(Roche NimbleGen) and paired-end sequencing per-
formed on Illumina HiSeq platform. Point mutations
were detected as previously described [26], using the
parental cell lines as controls. Briefly, point mutations
specific to resistant samples were called with VarScan2
somatic [27], with the following parameters: strand-filter
1, min-coverage-normal 8, min-coverage-tumor 6, som-
atic-p-value 1, normal-purity 1, min-var-freq 0,05. Par-
ental cell line was used as the normal control. Mutation
calling was done within the exome capture target re-
gions of the NimbleGen SeqCap EZ v2 capture kit and
the flanking 500 bps. Mutations were annotated with
SnpEff [28] using the Ensembl v66 annotation database.
To filter out misclassified germline variants, common
population variants included in dbSNP version 135 were
removed. Remaining non-synonymous mutations were
visually validated using the Integrated Genomics Viewer
(Broad Institute). Mutations with p < 0,05 and resistant
variant frequency >30 % were deemed high confidence.
Known false positive point mutations [29] were ex-
cluded. Exome-sequencing data was also analyzed using
the sequence alignment and variant calling pipeline
VCP. As input in the CNV analysis we used alignments
in BAM format, as well as identified variants in all sam-
ples [30] (and unpublished). All exome sequencing cap-
ture kit target regions less than 76 bp apart were merged
with each other. An RPKM (reads per kilobase of target
region length per million mapped reads) copy number
value was calculated separately for every target region,
followed by filtering out regions with sequencing cover-
age lower than 25x. Finally, relative log2 copy number
ratios for sample (drug-resistant variant) divided by ref-
erence (parental cell line) were calculated and seg-
mented using Circular Binary Segmentation [31]. Plots
of copy number, segmentation and variant allele fre-
quencies in capture target regions were visualized using
R. Gene level copy number data for all human genes in
Ensembl database v67 was calculated by assigning a gene
the value of the CNV data segment that it overlapped.
When a gene overlapped more than one segment, the
gene was assigned a copy number value based on a
modification of the extreme method option in GISTIC2
[32–34] as follows: the gene was given the lowest seg-
ment log2 value in case any overlapped segment had
log2 ratio < = −0,6 and the highest segment value if any
overlapped segment had log2 ratio > = 0,5. If all segments
the gene overlapped had log2 ratio > −0,6 and < 0,5; the
gene was assigned the median log2 ratio of all overlapped
segments. Thresholds for copy number changes were de-
termined based on samples (not published here) with
known copy number differences, such as male vs female
comparisons on chromosome X, as well as trisomies ob-
served in karyotyping of cells during routine diagnostics.
Based on these, the limits were set at −0,4 (heterozygous
deletion), −1,2 (homozygous deletion), +0,5 (gain) and
+1,3 (amplification). Raw exome-sequencing data have
been deposited in the NCBI Sequence Read Archive [SRP:
SRP050366].
Drug sensitivity and resistance testing (DSRT)
DSRT with the FIMM FO2Baq library containing 279
approved and investigational oncology drugs was done
as previously described [26] with minor modifications.
Briefly, drugs were dissolved and plated in five different
concentrations covering a 10 000-fold concentration
range into the wells of 384-well plates. Optimized
amounts of cells were then seeded into the wells in their
normal growth media, i.e. parental cells in normal media
and tamoxifen-resistant cells in media supplemented
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with 1 μM 4-OH-tamoxifen. Thus, this set-up allows for
measurement of permanent drug response changes cor-
responding to long-term tamoxifen treatment used in
the clinical setting, and allows for any combinatorial
drug responses to be observed. A further Cells were in-
cubated at 37 °C for 72 h and viability measured by
CellTiter-Glo Cell Viability Assay with the PHERAstar
plate reader. Data were normalized to negative (DMSO
only) as well as positive (100 μmol/l benzethonium
chloride) controls. The logistic dose–response curves
were estimated using the Marquardt-Levenberg algo-
rithm and implemented in the in-house bioinformatic
pipeline Breeze. The dose–response curves were then
employed to quantitatively profile drug responses, i.e.
the Drug Sensitivity Score (DSS), which is based on the
estimated logistic model parameters, and the DSS differ-
ence, which quantifies the differential drug response be-
tween tamoxifen-resistant and parental cells, as
previously described [26, 35]. We found that |dDSS| = 5
cutoff lies in the tail end of the distribution with 9.7 %
of values above the cutoff. With a two-tailed distribution
(signed DSS), this would correspond to ca. 5 % “hit rate”,
which we deemed as appropriate for such a drug discov-
ery approach. Clustering of the DSS response differences
across resistant/parental cell line pairs was performed
using unsupervised hierarchical complete-linkage clus-
tering, using Spearman and Euclidean distance measures
of the drug and sample profiles, respectively, and visual-
ized as a heat map [35]. In order to identify drugs that
significantly change their efficacy as the cells gain resist-
ance to tamoxifen, we performed rank product analysis
[36] at false discovery rate of 5 % (q < 0,05) by compar-
ing drug response profiles in the parental cells against
response profiles in the tamoxifen-resistant cells. The
average DSS activity of a drug in all parental cell lines
was plotted against the average DSS activity in the resist-
ant clones. The drugs selected from the rank product
analysis were considered as significant hits and displayed
as colored dots. Luminal A or B subtype-specific drugs
were identified (Additional file 2) based on the known
subtypes of the parental cells [37].
Construction of drug sensitivity and co-resistance
networks
To visualize drug sensitivity and resistance networks in
each resistant/parental cell line pair, drugs with DSS dif-
ference >5 (sensitivity) or < −5 (co-resistance) were se-
lected. For each drug, specific target molecules were
defined using the KIBA (Kinase Inhibitor BioActivity)
-score [38] as follows: First, drug target bioactivity (Ki,
Kd and IC50) values were extracted from the ChEMBL
database (https://www.ebi.ac.uk/chembl), and integrated
KIBA-score was calculated for each drug-target pair. A
low KIBA-score indicates a high binding affinity of the
drug with the target. Amongst the set of targets for a
drug, if the target with highest binding affinity had
KIBA-score of <0,1, the specific target threshold was
considered to be 50-fold the lowest KIBA-value; other-
wise KIBA-score <3 units was considered as the specific
target threshold. Second, to capture the connection be-
tween genomic changes and drug-target genes of the
most effective drugs in each resistant cell model com-
pared to its parental cell line, network analysis and
visualization was done on KIBA-scored specific targets
genes of the sensitizing or desensitizing drugs using In-
genuity Pathway Analysis application (Ingenuity® Sys-
tems, Qiagen). The IPA system is based on the Ingenuity
Pathways Knowledge Base, which is a repository of cu-
rated biological interactions, and functional annotations
between proteins, genes, complexes extracted from sci-
entific articles. The network consists of thousands of
nodes and the edges represent experimentally observed
cause-effect relationships that are related to direct phys-
ical interactions or regulatory interactions events like
expression, transcription, activation and molecular mod-
ifications. Network edges are also associated with a dir-
ection of the causal effect, i.e. either activating or
inhibiting [39]. Sensitizing and desensitizing drugs were
considered separately. We required each resistant/paren-
tal cell line pair to have at least three effector drugs with
a DSS difference >5 to enable network building based on
their target genes, discarding the sensitivity networks for
MCF-7 Tam1 and ZR-75-1 Tam1 as each of them had
one effector drug only. The target molecule networks
representing the most effective sensitizing or desensitiz-
ing drugs were merged, and then adjusted to keep the
edges that were human-specific and high confidence.
The resulting networks were then extended to upstream
neighboring molecules to reveal connections with genes
containing copy number variations or somatic mutations
within the target networks. In the IPA framework, up-
stream molecules are defined as the genes that have
been shown to affect the gene expression in some dir-
ect/indirect way [39]. The IPA network generation algo-
rithm considers all the immediate upstream molecules
separated by one degree from the nodes in the current
network, where priority is given to those genes having
maximum number of overlaps with the existing network.
Furthermore, we merged the IPA canonical pathway for
Estrogen Receptor Signaling (www.qiagen.com) with the
networks utilizing the IPA overlay tool.
Results
Development and characterization of long-term
tamoxifen-treated cell lines
To study the development of tamoxifen resistance across
distinct molecular backgrounds, we established seven
long-term tamoxifen-treated cell lines originating from
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four parental cell types; MCF-7, T-47D, ZR-75-1 and
BT-474. We exposed these ER-positive, initially
tamoxifen-responsive cells to continuous 1 μM 4-OH-
tamoxifen treatment (hereafter tamoxifen) for 8 to 12
months (Fig. 1). A steady concentration of tamoxifen
with clear inhibitory effect on ER-mediated transcription
was chosen to mimic the exposure of patients to the
drug in the clinic. In the course of the treatment, all cell
cultures underwent cell death leaving a few founder cells
that then recovered and repopulated the culture plates.
Once stable, the cultures were molecularly characterized
and subjected to pharmacogenomic profiling through
drug sensitivity and resistance testing (DSRT) and
exome-sequencing (Fig. 1). To confirm the resistant phe-
notypes, we assessed the viability of the cells upon in-
creasing tamoxifen concentrations. All resistant cells
showed increased tolerance towards tamoxifen compared
to the parental cells, verifying the resistance development
(Additional file 3A). For further characterization, we stud-
ied the cell cycle properties, functionality and levels of ER,
and estrogen-responsivity of the long-term tamoxifen-
treated cells. Resistant cell clones exhibited altered cell
cycle properties, with a higher fraction of cells in the G0/
G1 phase (Additional file 3B). All resistant cells had di-
minished ER target gene transcription, whereas the level
of ER itself either increased or decreased depending on
the clone (Additional file 4). Estradiol (E2) deprivation
and subsequent addition of estradiol back to the cells re-
vealed aberrant levels of ER target gene transcription, indi-
cating that upon acquiring resistance to the ER antagonist
tamoxifen, transcriptional regulation in response to the
natural ligand of the receptor, estradiol, is disturbed.
Acquired sensitivities and co-resistances upon
development of tamoxifen resistance
To uncover drug response profiles associated with long-
term tamoxifen treatment mimicking the prolonged ex-
posure to the drug used in the clinic, we conducted drug
sensitivity and resistance testing (DSRT) [26] with 279
FDA/EMA-approved and investigational oncology drugs
ranging from conventional chemotherapeutics to a var-
iety of targeted drugs (Additional files 5 and 6). We
quantified the overall drug responses for each compound
in each cell line using drug sensitivity score (DSS) [35].
Targeted drugs generally had higher efficacy than the
standard chemotherapeutics, as seen for example with
treated with 1µM 4-OH-tamoxifen for 8-12 months
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Fig. 1 Development and analyses of the parental breast cancer cell lines and their tamoxifen-resistant variants. a Schematic representation of the
four parental cell lines (MCF-7, T-47D, ZR-75-1 and BT-474) and their seven tamoxifen-resistant variants (arrows) that were developed through
continuous tamoxifen-treatment. b Followed by molecular and cell biological characterization (1), drug sensitivity and resistance testing and
exome-sequencing to detect point mutations (single nucleotide polymorphisms, SNP) and copy number variations (CNV) (2), the data was then
integrated and the pharmacogenomic relationships visualized through network modeling (3). DT = Drug target. To reveal drug responses and
genetic changes associated with tamoxifen resistance, all analyses were performed by comparing each tamoxifen-resistant cell line to its parental
control cell line
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the HER2/EGFR inhibitors lapatinib, afatinib and nerati-
nib that were efficacious only against the BT-474 paren-
tal cells that express these receptors (Additional file 2A
and B). We then calculated the DSS difference between
the tamoxifen-resistant and their parental cells to reveal
the cell line-specific drug sensitivity and resistance pat-
terns associated with the resistance to tamoxifen. Inter-
estingly, all tamoxifen-resistant cell lines displayed
distinct drug response profiles, with a few overlapping
responses (Fig. 2a). Overall, the drug responses of the re-
sistant clones derived from the same parentals resem-
bled each other more than those of the other resistant
clones, and a few shared sensitivities arose, such as to-
wards tyrosine kinase (gefinitib, ibrutinib) and cdk inhib-
itors (alvocidib, SNS-032) in the BT-474 clones.
However, in T-47D and ZR-75-1, only a few common
drug sensitivities and co-resistance patterns evolved be-
tween the two subclones, indicating clonal evolution
(Fig. 2b).
Resistant cells accumulate genetic alterations throughout
their genomes
To define the mutational landscape of the tamoxifen-
resistant cell clones and to identify potential genomic
markers for drug sensitivity and resistance, we con-
ducted exome-sequencing on each isogenic parental-
resistant cell line pair. In order to identify resistance-
specific point mutations and copy number variations,
each tamoxifen-resistant cell line was compared to its
parental cell line. Between 31,8 and 83,0 million
uniquely mapping reads per sample were obtained with
an average coverage of 43,7x (Additional file 7). We
found genetic changes scattered along the genomes of
the tamoxifen-resistant cells (Additional files 8, 9 and
10). We identified approximately 250 to 350 non-
synonymous mutations per resistant cell line (Additional
file 9), and for integration with copy number alterations,
selected the high confidence ones. Interestingly, only a
limited panel of mutated genes was shared between the
two clones derived from the same parental cells includ-
ing TIMM23 and RP11-368 J21.2.1 in ZR-75-1 Tam1
and Tam2, and TNS1, PTH2R and NHLRC2 in BT-474
Tam1 and Tam2. None of the point mutations were
shared between T-47D Tam1 and Tam2 (Additional file
8). All resistant clones displayed marked copy number
aberrations, which were primarily large deletions, with
the exception of ZR-75-1 Tam1 that only harbored gains.
Chromosomes X and seven were recurrently altered,
with few larger deletions (such as a homo- and heterozy-
gous deletion of Xq in MCF-7 Tam1 and heterozygous
deletion of 7q in T-47D Tam1), as well as several smaller
aberrations found in each resistant cell line (Additional
files 8 and 10). Again, just a few genes displaying copy
number alterations were shared between the two
resistant clones derived from ZR-75-1 and BT-474, im-
plying genetic clonal divergence.
T-47D tamoxifen-resistant cells develop shared as well as
individual sensitivities
To reveal the pharmacogenomic relationships between
the drug response profiles and the genetic alterations,
we integrated the drug response and genetic profiling
data. Specifically, based on the DSS differences, we first
selected the most pronounced drug response changes
between each parental-resistant cell line pair. To correl-
ate the genomic alterations with the drug responses we
then constructed sensitivity and resistance networks
among the target genes of the selected drugs, and
mapped the point mutations and CNV changes onto
these molecular networks as detailed in Materials and
Methods, Construction of drug sensitivity and co-
resistance networks. We also merged the obtained net-
works with the IPA canonical pathway for Estrogen Re-
ceptor Signaling. However, only in two out of fourteen
networks more than two overlapping molecules were
found, indicating that only a fraction of them are actu-
ally connected with the ER signaling pathway and hence,
in the majority of cases, the sensitivity and resistance
mechanisms arise independently of ER. Overall, the
number of genetic alterations mapping onto the drug
target networks varied between 11 (T-47D Tam2 sensi-
tivity network) and 0 (some ZR-75-1 and BT-474 net-
works), and converged into a number of target genes. In
all but two networks (BT-474 Tam2 and ZR-75-1 Tam2
sensitivity) all the observed CNV changes were heterozy-
gous deletions (Figs. 3, 4, 5 and 6 and Additional files 11
and 12). Of the two tamoxifen-resistant clones generated
from the parental T-47D, both exhibited mostly sensi-
tized profiles. T-47D Tam1 and Tam2 both acquired sen-
sitivity towards the SRC/ABL-family inhibitors; the
Tam1 cells towards three of them: ponatinib, dasatinib
and KX2-391; and the Tam2 cells against two of them:
dasatinib and KX2-391 (Figs. 3 and 4). The Tam1 cells
also became sensitive towards selumetinib, a MEK in-
hibitor, and the Tam2 cells towards VX-11E, an ERK1/2
inhibitor. In addition, sensitivity towards BCL-family in-
hibitors (navitoclax, obatoclax), and RAF inhibitors (re-
gorafenib, RAF265) was observed in Tam1, but not in
Tam2. Reflecting the acquired drug sensitivities, multiple
target genes of these drugs or their upstream effectors
converged into the same sensitivity networks, and not-
ably, many of these target genes also harbored genetic
changes.
Increased sensitivity towards HER2/EGFR inhibitors
Similar to the T-47D resistant clones, the tamoxifen-
resistant BT-474 s displayed mainly acquisition of drug
sensitivities. However, unlike any of the other tamoxifen-
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resistant clones, BT-474 Tam1 and Tam2 developed vul-
nerability to several EGFR/HER2-inhibitors (gefitinib,
ibrutinib, neratinib, nintedanib; Fig. 5a, c and Fig. 6a, c).
Notably, the parental BT-474 s also showed sensitivity
towards HER2/EGFR inhibitors (Additional file 2), which
was selectively enhanced upon developing resistance to
tamoxifen. In addition, sensitivity towards cdk-inhibitors
(SNS-032, alvocidib) emerged, and several of the drugs’
target genes or their upstream effectors also harbored
CNV changes (Fig. 6d). Both tamoxifen-resistant BT-474
clones also developed sensitivity towards the ERK1/2-
inhibitor VX-11E and the JAK2-inhibitor gandotinib.
BT-474 Tam2 also displayed gain of JAK2, possibly
explaining the developing sensitivity towards gandotinib
(Fig. 6d).
Co-resistance against multiple drugs evolves across the
tamoxifen-resistant cells
In addition to emerging drug sensitivities, we also ob-
served acquired co-resistances upon development of
tamoxifen resistance. In contrast to the other resistant
cells that developed both new sensitivities as well as co-
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Kangaspeska et al. BMC Cancer  (2016) 16:378 Page 8 of 17
resistances, the tamoxifen-resistant MCF-7 Tam1 dis-
played an overwhelmingly co-resistant drug response
profile, including resistance towards many chemothera-
peutics (camptothecin, vincristine, SNS-032), but also
several mTOR- and two HDAC-inhibitors (dactolisib,
AZD8055, sirolimus, panobinostat, belinostat) (Add-
itional file 11). In the two T47-D tamoxifen clones, the
resistance networks were markedly different, with T47-D
Tam1 displaying resistance merely to four agents, two of
which were chemotherapeutics, whereas T-47D Tam2
cells exhibited co-resistance to a large variety of drugs.
These included some of the same drugs as for the Tam1
clone, and additionally Tam2 showed resistance to four
mTOR- and two HDAC-inhibitors (Figs. 3 and 4). Both
ZR-75-1 as well as the BT-474 resistant clones developed
co-resistance to several chemotherapeutics (Figs. 5 and
6, Additional files 5, 6, 12), with the ZR-75-1 networks
being nearly identical, reflecting the high similarity be-
tween their drug response patterns. Interestingly, the
BT-474 Tam1 cells additionally showed resistance to
rapamycin and everolimus, two mTOR inhibitors, as
well as to AT 101, a BCL-family inhibitor (Fig. 5). Col-
lectively, compared to the sensitivity profiles, the resist-
ance networks demonstrated less variance between the
different tamoxifen-resistant clones, with the majority of
them developing co-resistance towards common chemo-
therapeutics (Table 1).
Shared sensitivities and co-resistances
We next addressed the development of common sensi-
tivities and co-resistances upon acquisition of tamoxifen
resistance. Cross-comparison of the drug response pro-
files across all tamoxifen-resistant clones revealed that
several of them developed sensitivity towards the ERK1/
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2-inhibitor VX-11E, the proteasome-inhibitor bortezo-
mib, and the FAAH-inhibitor PF-3845. Common co-
resistance towards the survivin-inhibitor YM155 and the
chemotherapeutic agent paclitaxel also occurred (Fig. 7a).
Furthermore, even with the limited sample size, these
shared responses were statistically significant (rank prod-
uct analysis, Fig. 7b). To further assess the EGFR/ERK
signaling pathway in the resistant cells, we selected the
MEK/ERK inhibitors for which a differential drug sensi-
tivity score was obtained, i.e. VX-11E and selumetinib.
The concentration range was selected based on the IC50
of the drugs in the individual cell lines (Additional file
5). We then cultured the cells either in their default cul-
ture media, or with increasing concentrations of VX-
11E, or with VX-11E and selumetinib concomitantly,
and performed Western blotting with ERK1/2 and EGFR
antibodies (Fig. 7c). The basal levels of these unpho-
sphorylated as well as phosphorylated signaling proteins
were lowered in the tamoxifen-resistant cells compared
to the parentals (Fig. 7c), but upon increasing concentra-
tions of VX-11E, slight increase in phosphorylated
ERK1/2 was observed in the T-47Ds. However, upon
additional inhibition of MEK with selumetinib, the in-
crease in phosphorylated ERK1/2 was diminished.
Discussion
In the present study, we report the development and sys-
tematic characterization of seven long-term tamoxifen-
treated cell lines, and by pharmacogenomic profiling,
determine the drug response profiles and mutational land-
scapes of these drug-resistant models. Different in vitro
and in vivo models of endocrine-resistance have been de-
veloped to explore common mechanisms behind resist-
ance development [9–11, 19, 20, 22, 40–50] However, to
our knowledge, this is the first comprehensive drug testing
study with hundreds of oncology compounds across a
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panel of several tamoxifen-resistant models. Using this ap-
proach, we identify clone-specific molecular networks
reflecting the diversity of pathways leading to endocrine
resistance. It is noteworthy that as the availability of clin-
ical data sets on diagnosed acquired tamoxifen resistance
with response/survival data are essentially non-existent
to date, the resistant/sensitive cell line models and asso-
ciated data sets presented here form a valuable research
resource.
Concurrently with developing tamoxifen resistance,
novel drug vulnerabilities emerge. Here, we identified
common, cell type-, and cell clone-specific sensitivities.
The most important of these are listed in Table 1. Add-
itionally, several of the sensitizing drugs are in clinical
trials for treatment of advanced or metastatic breast
cancer. However, possible correlation between patient
enrollment criteria, observed molecular mechanisms and
the sensitivities and co-resistances identified here re-
mains to be investigated.
All resistant cell lines except one (MCF-7 Tam1) ex-
hibited gained sensitivity towards the ERK1/2 inhibitor
VX-11E. ERK1/2 inhibition prevents its autophosphoryl-
ation [10, 51] and results in reduced phosphorylation
and thereby also decreased activation of ER [9]. Over-
activity of ERK1/2 has been shown to associate with loss
of ER, and decreased levels of ER are also seen in the
majority of our tamoxifen-resistant cell lines (Additional
file 4) [52]. However, the basal levels of unphosphory-
lated or phosphorylated EGFR/ERK are not elevated in
the tamoxifen resistant lines; rather the opposite, i.e. de-
crease in basal levels as well as dephosphorylation of
ERK1/2 and EGFR is observed (Fig. 7c and data not
shown). We therefore anticipate that increased phos-
phorylation of these signaling proteins does not explain
the observed sensitivity towards VX-11E. Interestingly,
upon increasing concentrations of VX-11E, slight in-
crease in phosphorylated ERK1/2 is observed in the T-
47D Tam clones. However, upon additional inhibition of
MEK with selumetinib, this effect is diminished. The ef-
fect of VX-11E inducing ERK1/2 phosphorylation has
also previously been reported [53] and might therefore
reflect a general mode of action especially as the same
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effect is observed also in our parental cells (Fig. 7c). It
could therefore be speculated that already a short-term
tamoxifen treatment causes an effect on the levels of
phosphorylated ERK1/2 and that long-term exposure
leads to, at least partial, down-regulation of EGFR and
ERK1/2. As cells are challenged with increasing concen-
trations of an ERK1/2 inhibitor (VX-11E), an increase in
ERK1/2 phosphorylation is seen, with concomitant cell
killing of the tamoxifen-resistant cells observed in the
drug screen. However, further studies to elucidate the
exact mechanisms are needed.
We also identified bortezomib, a proteasome inhibitor,
as a sensitizing agent (Figs. 5, 6 and 7 and Additional file
12, Table 1). A direct role for bortezomib in reversing
tamoxifen resistance has not been demonstrated before,
although a link between proteasome function and estro-
gen receptor -mediated transcription has been suggested
[54], and bortezomib has recently been shown to en-
hance endocrine treatment in cell line models as well as
in humans [11–13].
In addition to shared sensitivity to VX-11E and borte-
zomib in the tamoxifen-resistant cells, we also identified
cell line specific drug sensitivities (Table 1, Figs. 3, 4, 5
and 6, Additional files 11 and 12). T-47D Tam1 and
Tam2 cells displayed sensitivity towards the SRC-family
inhibitor KX2-391 and the dual ABL/SRC-inhibitors
dasatinib and ponatinib (Figs. 3 and 4). This is in agree-
ment with recent findings [20, 55]. Another SRC-
inhibitor, SU6656, has also been reported to inhibit
growth of tamoxifen-resistant cells [42], highlighting the
potential of SRC-inhibition in overcoming endocrine
resistance. Interestingly, dasatinib has been shown to
overcome tamoxifen resistance in MCF-7/fibroblast co-
culture, and it is currently undergoing clinical trials on
metastasized ER-positive breast cancer.
Upon acquiring resistance to tamoxifen, the T-47D
Tam1 cells also gained sensitivity towards the BCL-
family inhibitors navitoclax and obatoclax (Fig. 3). BCL-
2 family proteins BCL-2, BCL2L1, BCL2L10 and MCL1,
represented in the network, are major negative regula-
tors of apoptosis, and thus, upregulation of their expres-
sion might offer the tamoxifen-challenged cells means to
overcome resistance, as well as downregulation of BAD,
a proapoptotic regulator. Indeed, BCL-2 has been indi-
cated in tamoxifen resistance, and consequently, a BCL-
2 inhibitor, ABT-737, has been reported to restore sensi-
tivity [56]. Additionally, tamoxifen treated patients with
low level of BAD expression had a worse prognosis [57].
The T-47D Tam1 cells also displayed sensitivity towards
RAF-inhibitors BAY 73–4506 and RAF265. This is in
line with previous findings on overexpression of RAF1
promoting tamoxifen-resistant growth [58]. Both navito-
clax and BAY 73–4506 are being investigated for treat-
ment of different cancers, navitoclax for lung cancer and
lymphoma, and BAY 73–4506 for metastatic colorectal
cancer among others. Our results, and those from others
[56–58] suggest that BCL- and RAF-inhibitors might
offer means to treat also endocrine-resistant breast
cancer.
We also identified sensitizers with preference for the
luminal B-derived tamoxifen-resistant cells, BT-474
Tam1 and Tam2. These included the cdk-inhibitors
Table 1 Tamoxifen-resistant cells develop individual as well as
common drug sensitivities and co-resistances. Sensitizing and
desensitizing drugs, drug target classes, specific target genes
and as well as affected cell lines are listed
Sensitivity towards Drug target class Specific
target gene
Observed in
cell line
Navitoclax, Obatoclax BCL-family BCL2L1 T-47D Tam1
BAD
RAF265, Ponatinib RAF-family RAF1 T-47D Tam1
Dasatinib, KX2-391 SRC/ABL ABL1 T-47D Tam1
& Tam2
SRC
VX-11E MAPK1 MAPK1 T-47D Tam2,
BT-474 Tam2,
ZR-75-1 Tam2
Gefitinib, Ibrutinib,
Neratinib, Nintedanib
HER2/EGFR ERBB2 BT-474 Tam1
& Tam2
ERBB4
ERBB3
Vinblastine Tubulins TUBA1A T-47D Tam2
TUBA4A
TUBA1C
TUBB6
PF-3845 FAAH FAAH ZR-75-1 Tam2
Bortezomib PSMB-family PSMB5 ZR-75-1 Tam2
Resistance towards Drug target class Specific
target gene
Observed in
cell line
YM155 BIRC5 BIRC5 T-47D Tam1
& Tam2,
MCF-7 Tam1,
BT-474 &
Tam2
Quisinostat,
Panobinostat
HDACs HDAC1 T-47D Tam2,
MCF-7 Tam1
HDAC6
Docetaxel,
Paclitaxel
Tubulins TUBA1C BT-474 Tam2
TUBB2A
TUBB3
TUBB
TUBB4B
TUBB6
Temsirolimus,
Everolimus,
Ridaforolimus,
INK128, Sirolimus,
AZD8055, Dactolisib
mTOR mTOR MCF-7 Tam1
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SNS-032 and alvocidib, along with the EGFR-inhibitor
gefinitib and the Btk-inhibitor PCI-32765, and several
HER2/EGFR-inhibitors (Figs. 5 and 6). Crosstalk
between ER and ERBB2/EGFR pathways has been shown
to be activated in tamoxifen resistance [59]. Recently,
the EGFR/HER2 dual inhibitor AZD8931 was also
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suggested to inhibit growth of MCF-7 or T-47D
tamoxifen-resistant cells in xenograft models [60]. It is
noteworthy that in our study, the parental BT-474 cells,
unlike all others presented here, initially amplify and
overexpress HER2, and display some sensitivity towards
HER2/EGFR-inhibitors (Additional file 2). Interestingly,
as tamoxifen resistance develops, the cells become more
sensitive to several of the HER2/EGFR-inhibitors and in-
deed, the combined use of growth factor receptor kinase
inhibitors in conjunction with tamoxifen has been sug-
gested to circumvent endocrine resistance [45], and
combination therapy with antihormone and gefinitib has
demonstrated resensitization to tamoxifen in xenografts
[61, 62]. However, our results on decreasing EGFR /
phospho-EGFR levels upon acquired resistance (Fig. 7c)
indicate that mechanisms other than direct upregulation
of the EGFR pathway are responsible for the observed
gained sensitivity.
Development of primary drug resistance in cancer
treatment frequently results in the emergence of second-
ary resistances. Here, we discovered that upon acquiring
tamoxifen resistance, all of the resistant cells acquired
co-resistance towards at least one chemotherapeutic
agent, such as paclitaxel, docetaxel, vincristine, vinblast-
ine or topotecan (Figs. 2, 3, 4, 5, 6 and 7, Table 1 and
Additional files 5, 11 and 12). Even though chemoresis-
tance has been associated with the estrogen receptor
[24], the co-resistance observed here may rather reflect
the slowed-down growth of many of the resistance
clones, and may therefore propose a uniform mechanism
for paclitaxel resistance (Additional file 3). However,
selective co-resistance still occurs, as the cells do not be-
come universally co-resistant against all chemotherapeu-
tics. Nevertheless, general down-regulation of cellular
functions is especially evident with the tamoxifen-
resistant MCF-7 Tam1 cells, which not only possess an
overwhelmingly co-resistant drug response profile, but
also down-regulate cell signaling (Additional files 3, 4,
11). Indeed, already a short-term tamoxifen-treatment of
MCF-7 cells triggers a predominant down-regulation of
gene expression [63], suggesting that depending on the
molecular background, some tamoxifen-resistant cells
might exhibit an intrinsically more unresponsive profile.
Interestingly, every single tamoxifen-resistant cell line
was also more resistant to the survivin (BIRC5-) inhibi-
tor YM155 than their parental counterparts (Figs. 2, 3, 4,
5, 6 and 7, Table 1 and Additional files 5, 11 and 12),
suggesting a role for survivin in development of tamoxi-
fen resistance. Survivin has recently been associated with
resistance to chemo- or hormonal therapy, and has been
identified to predict poor clinical outcome via ERBB2-
mediated overexpression [47]. Furthermore, siRNA-
knock down of BIRC5 has been shown to enhance cell
sensitivity to tamoxifen [64]. Alternatively, it has been
speculated that uptake of YM155 is dependent on cell
membrane a solute carriers, encoded by the SLC35F2
gene [65]. Upon resistance development, expression of
the solute carriers possibly decreases and consequently,
less YM155 enters the cells making them resistant to the
drug.
As initiation and development of acquired tamoxifen
resistance are largely thought to be driven by genetic ad-
aptations [3–5, 7] we inspected the genetic landscape of
the drug-resistant cells by exome-sequencing and corre-
lated the findings with our drug profiling data.
Tamoxifen-resistant cells accumulated point mutations
and copy number changes throughout their genomes,
with only some of the changes being common between
two resistant clones originating from the same parental
cells, implying clonal divergence (Additional files 8, 9
and 10). Whilst many of the genetic aberrations that
have been associated with endocrine resistance previ-
ously were also recapitulated here, our data as a whole
demonstrate that new sensitivities may develop largely
independent of the genetic changes, and in fact, anties-
trogen resistance can be seen even in the absence of any
evident mutations [66]. Analogous phenomenon has
been noted in leukemic cells [67]. Accumulation of nu-
merous genomic aberrations can trigger resistance devel-
opment [20], but mutations can also be carried along as
passengers as a result of selection pressure, rather than
emerge as true evolutionary drivers [68]. The data pre-
sented here demonstrate that in the majority of cases,
no single genetic alteration can be identified as respon-
sible for the drug response, but on the contrary, multiple
target genes of the drugs converge into the same re-
sponse networks, and many of these target genes also
harbor genetic changes. Therefore, resistance develop-
ment is likely to involve complex interactions compris-
ing genetic as well as transcriptional and epigenetic
mechanisms, or other adaptive changes in cell signaling.
Conclusion
Taken together, the results presented in this study dem-
onstrate that upon acquiring endocrine-resistance, breast
cancer cells follow different paths to resistance, as shown
by distinct genomic evolution. As a consequence, gained
sensitivity as well as co-resistance towards a variety of
other agents evolves. In addition to common vulnerabil-
ity towards ERK1/2- and proteasome-inhibitors, we also
identified a universal co-resistance towards the survivin-
inhibitor YM155 in tamoxifen-resistant cells. Drug re-
sponse profiles between cell clones derived from the same
parental cells differed markedly, and different members of
the same drug classes could be either sensitizing or desen-
sitizing. This suggests that resistance mechanisms vary
within tumors, among patients and with time, highlighting
the need for personalized diagnosis and clone-targeting
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therapies in the treatment of tamoxifen-resistant breast
cancer. As shown here, prediction of drug responses can
be difficult based on genomic profiling alone. This study
provides a reference set of materials (drug-resistant cell
lines), and their cell biological, genomic and drug response
profiling for future studies aiming to test novel therapies
for breast cancer with acquired tamoxifen resistance.
Additional files
Additional file 1: Primer sequences. (XLSX 10 kb)
Additional file 2: Parental cells show sensitivity and selectivity towards
known breast cancer drugs according to their subtype. (A) Drug Sensitivity
Scores (DSS) of known breast cancer treatment drugs. (B) DSS of drugs
specific to luminal A-(left) and luminal B-subtypes (right). Results are extracted
from the data on all drugs tested in all cell lines, presented in Additional file 5.
The drugs specific to parental luminal A and B subtypes were identified based
on their DSS scores. (PDF 423 kb)
Additional file 3: Growth and tamoxifen-tolerance of tamoxifen-resistant
cells. (A) CTG-viability measurement of tamoxifen-resistant vs parental cells
treated with increasing concentrations of tamoxifen. (B) Measurement of
active DNA synthesis by FACS-analysis showing accumulation of resistant
cells in the G0/G1 phase of the cell cycle. (PDF 1035 kb)
Additional file 4: Estrogen responsivity of ERα-mediated transcription in
the tamoxifen-resistant cells. (A) Quantitative RT-PCR showing decreased
ERα target gene expression in the resistant cells. (B) Quantitative RT-PCR
of the ERα target gene pS2 expression upon estradiol withdrawal and
subsequent addition of estradiol back to the cells. (C) Western blotting
displaying altered protein levels of ERα in the resistant cells. A.u. = arbitrary
units, E2 = 17β-estradiol. Error bars show standard deviation. (PDF 704 kb)
Additional file 5: Drug Sensitivity Scores. Drugs used in the study, their
approval status and Drug Sensitivity Scores (DSS) of the tamoxifen-resistant
and their parental cell lines. Max.Conc [nM] = maximum concentration,
Min.Conc [nM] =minimum concentration, MAX =maximum % inhibition,
D1 [% inhibition]… D5 [% inhibition] = % inhibition from the lowest (D1) to
the highest drug concentration (D5). (XLSX 478 kb)
Additional file 6: DSRT statistics. (XLSX 9 kb)
Additional file 7: Exome-sequencing reads. (XLSX 10 kb)
Additional file 8: Copy number alterations and point mutations are
scattered throughout the genomes of the tamoxifen-resistant cells. (A)
Relative copy number of each resistant cell line measured by
exome-sequencing and plotted as log2 ratio of resistant vs parental
cell line (colored dots). Copy number gains/amplifications and
losses/deletions are visible as peaks and valleys in the red segmentation line,
respectively. Chromosomes are numbered and highlighted in alternating
colors. High confidence point mutations (p < 0,05 and resistant/parental
frequency >30 %) are depicted above the segmentation line. (B) Venn
diagrams show overlap of point mutations (black) and genes altered by
CNVs (red) between the tamoxifen-resistant clones derived from same
parental cells. (PDF 735 kb)
Additional file 9: Point mutations from exome-sequencing. Point
mutations, sequencing reads and mutation frequency in tamoxifen-
resistant cells (Resistant Reference Reads, Resistant Variant Reads, Resistant
Variant Frequency) compared to their parental cell lines (Parental
Reference Reads, Parental Variant Reads, Parental Variant Frequency)
revealed by exome-sequencing. Sample ID, chromosome, position,
reference and variant base, affected gene, effect, effect impact, and
p-values are also indicated. (XLSX 250 kb)
Additional file 10: Copy number variations from exome-sequencing.
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resistant MCF-7Tam1 vs parental cells reveal emerging sensitivities (above the
dotted line) and co-resistances (below the dotted line) upon acquiring
tamoxifen resistance. (B) Color legend of the drug target class. For
visualization purposes, the drugs were colored according to their target class
as indicated, and the coloring matched with their target genes. (C)
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in MCF-7 Tam1. Drugs without target genes in the networks are not
displayed. Drug targets (colored) and upstream molecules (uncolored)
are denoted as follows: ovals, molecules without genomic changes;
rectangles with solid line, molecules with copy number deletions, high
confidence (p < 0,05 and resistant/parental frequency >30 %) point mutations
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